NHS Consultant Medtech Advisor: GMC Rules and Rates

What "medtech advisor" actually means for a UK NHS consultant

Founders throw the label around loosely. Sometimes it means one hour on a call a month to sanity-check clinical logic. Sometimes it means running a full clinical validation study or acting as their named Clinical Safety Officer.

Only the first of those is casual work for a UK consultant. Everything past a monthly call touches your job plan, your GMC declarations, and, if you sit on a whole-time NHS contract, your right to accept the money at all.

Becoming an effective NHS consultant medtech advisor UK-side comes down to getting three things right before you sign anything: your contract type, your GMC disclosures, and how you price the work.

The MPT vs whole-time question comes before the day rate

Here is the opinion that shapes everything below: if you are doing more than one substantive advisory engagement, you should move to Maximum Part-Time (MPT). Trying to fit two or three healthtech contracts inside the whole-time private-practice cap turns every invoice into a compliance calculation and hands your NHS employer a valid reason to challenge you at appraisal.

The 2003 consultant contract caps private income on a whole-time (10 PA) contract at 10% of your gross NHS salary. A consultant on £115k whole-time can therefore only earn about £11.5k in private work before the trust can reasonably require a move to MPT. MPT pays 9/10ths of the whole-time salary and lifts the cap entirely.

Founders will never ask you which contract you hold. You need to know it yourself before you accept a retainer, an equity grant, or any engagement that assigns IP.

Reality check: MPT is administratively cleaner and financially better past roughly the £15k advisory income mark. Do not wait until the tax return to work this out.

Where GMC guidance actually bites

The GMC does not prohibit paid work for medtech companies. Good Medical Practice and the financial and commercial arrangements guidance require three things you have to operationalise, not just acknowledge.

First, declare the arrangement to your NHS employer in writing, ideally through job planning or the trust's declaration of interests register. Do this before the first invoice lands, not after.

Second, disclose the relationship to any patient whose care the product could touch. If you advise a company making a wound care device and you see wound patients on a Wednesday clinic, the disclosure is not optional.

Third, refuse fee structures or equity vesting schedules that tie your payment to product adoption at your trust. This is the single most cited failure mode at fitness to practise, and both defence unions have published increasingly pointed guidance on it.

Practical test: if the founder's contract makes your fee or equity vesting contingent on adoption at your NHS site, walk away. It is not survivable at MDU or MPS review.

Realistic day rates for a UK consultant in 2026

Founders quote wildly different numbers. Here is the honest range as of mid-2026, based on what UK consultants are accepting on Orbion Connect and comparable platforms.

• One-off expert call (60 minutes): £250 to £600, depending on speciality. Radiology, dermatology and cardiology sit at the top of that range.
• Structured advisory day (design review, workshop, protocol input): £1,500 to £3,000.
• Named clinical lead on a validation study: £15,000 to £45,000 for a six-month engagement, plus expenses.
• Named Clinical Safety Officer (DCB0129 or DCB0160): £8,000 to £20,000 per year as a retainer, plus incident work. Confirm indemnity implications with your defence union before signing.
• Advisory board seat (12 months, quarterly meetings, ad hoc input): £8,000 to £20,000 cash, sometimes replaced or supplemented by equity.

Under-priced advisory work damages the market for every consultant who follows you. If a Series A healthtech founder tells you their "standard" advisory rate is £300 a day, they are either negotiating hard or being advised badly. The number you accept sets the ceiling for the next consultant they contact.

Equity: when to take it and when to pass

Equity looks attractive because a 0.5% grant in a company that reaches a £100m outcome pays more than a decade of day rates. Most healthtech companies do not reach that outcome, and the ones that do usually take seven or more years to get there.

Take equity when three things are true together: the company is at seed or pre-seed, you can meaningfully shape the product roadmap or clinical evidence strategy, and vesting is time-based (typically 2 to 4 years, with a 1-year cliff) rather than tied to any NHS purchasing event.

Pass on equity when the company is Series B or later, when vesting is tied to adoption, or when the founder cannot articulate a plausible exit path. "We are talking to strategics" is not an exit path.

Orbion Connect publishes benchmark equity grants for clinical advisors by stage on our case studies page. The short version is 0.1% to 0.5% at seed, 0.05% to 0.15% at Series A, cash-only past Series B unless you are joining as a fractional Chief Medical Officer.

Three examples that show how this plays out

Startup example. A cardiothoracic consultant at a London teaching trust took a 0.4% equity grant plus a £1,200 day rate from a seed-stage AI ECG interpretation company in early 2026. She was on MPT, declared the arrangement at her job plan review, and negotiated vesting to be strictly time-based.

When the trust piloted the product a year later, she recused herself from the procurement panel and the decision was made cleanly. Her equity now vests without conflict, and she is the named clinical lead on the CE mark evidence package.

NHS institutional example. A large trust in the North West of England now requires all consultants doing paid medtech work to declare it through a central register within 30 days of signing a contract, following the NHS England guidance on managing conflicts of interest. Consultants who fail to declare face a formal HR letter, not just a comment at appraisal.

Assume your trust either has this policy already or will within 18 months.

Failure example. A consultant urologist accepted a £30,000 cash payment and 1% equity from a robotics company, with equity vesting tied to the company hitting a specified number of installed sites in the NHS. He then advocated for the product internally without declaring the equity structure.

The GMC investigation ran for 14 months and ended with a warning on his record. The specific failure was the vesting structure, not the equity itself.

What founders are actually paying you for

Founders pay you for three specific things: sharp clinical judgment on their next product decision, warm access to the people who make purchasing calls at trusts, and credibility that shortens the sales cycle. Your CV is not one of them, though many pitch decks list it for free.

If the founder is paying you and you are not moving one of those three needles, the contract will not survive their next cash-flow review. Better to renegotiate the scope than to be quietly dropped.

Price yourself on those three axes honestly. A radiology consultant who can shortcut a trust IT integration conversation is worth more per hour than a general physician doing a monthly product review, and both should be priced accordingly.

What to do this week

Check whether you are on whole-time or MPT. If you are on whole-time and plan to do meaningful advisory work, start the MPT conversation with your medical director at your next job plan review.

Register on Orbion Connect and complete the expertise profile, including the specific product areas you can speak to with authority. Founders search by product area, not by speciality, so a granular profile earns more inbound than a long CV. See about Orbion for how the matching works.

Draft your standard advisor agreement template before you need it. The moments after a founder asks "can we work together?" are the wrong time to work out your day rate, IP position, and conflict declarations from scratch.

Where to go next

If you are earlier in the arc, read our post on how to become a clinical advisor in UK healthtech for the fundamentals. If you are moving toward safety-critical work, how to become a Clinical Safety Officer is the natural next read. Founders reading this to understand what to budget should look at clinical advisor compensation in UK healthtech.